Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial - Zhu, A X; Park, J O; Ryoo, B-Y (Lancet Oncol, 2015)
, et al; REACH Trial Investigators.